ABSTRACT
BACKGROUND AND AIMS: The impact of advanced age on the optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary revascularization (PCI) is still greatly debated. Therefore, the aim of the present sub-analysis of the REDUCE trial was to assess the impact of age on the comparison between a short 3 months vs standard 12 months DAPT in ACS patients treated with the COMBO Dual Stent Therapy. METHODS: The REDUCE trial is a prospective, multicenter, investigator-initiated study that randomized ACS patients undergoing PCI with the COMBO drug eluting stent to either 3 or 12 months of DAPT. The study population was divided according to age (Subject(s)
Acute Coronary Syndrome
, Drug-Eluting Stents
, Percutaneous Coronary Intervention
, Acute Coronary Syndrome/diagnosis
, Acute Coronary Syndrome/drug therapy
, Aged
, Child, Preschool
, Drug Therapy, Combination
, Follow-Up Studies
, Humans
, Infant
, Male
, Percutaneous Coronary Intervention/adverse effects
, Platelet Aggregation Inhibitors/adverse effects
, Prospective Studies
, Stents
, Treatment Outcome
